Similarly, in a study of 55 dilated cardiomyopathy patients randomized to CD34+ cell transplantation or control, the treated group experienced a significant increase in % EF and exercise capacity, as well as reduced NT-proBNP and mortality rates [53]. The gene discussed is CD34; the disease is dilated cardiomyopathy.